23andMe Holding Co. (ME) Shares Outstanding: 0.03
Is 23andMe Holding Co.’s shares outstanding high or low?
23andMe Holding Co.'s shares outstanding of 0.03 is 15% above its 5-year average of 0.02, near the high end of its 5-year range (0.02–0.03).
3.30% above its 12-month average of 0.02.
ME Shares Outstanding Chart
ME Average Shares Outstanding Chart
ME Current vs Average Shares Outstanding Chart
ME Shares Outstanding Metrics
SHARES OUTSTANDING
0.03
SHARES OUTSTANDING AVG TTM
0.02
SHARES OUTSTANDING AVG 3Y
0.02
SHARES OUTSTANDING AVG 5Y
0.02
SHARES OUTSTANDING AVG 10Y
N/A
SHARES OUTSTANDING AVG 15Y
N/A
SHARES OUTSTANDING AVG 20Y
N/A
CURRENT VS TTM AVG
+3.30%
CURRENT VS 3Y AVG
+9.41%
CURRENT VS 5Y AVG
+14.72%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Share Structure
Shares Outstanding
25.82M
Float Shares
N/A
Stock Price
$0.61
Market Cap
$0.0B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 25.82M | +6.82% |
| 2024 | 24.17M | +7.06% |
| 2023 | 22.58M | +3.43% |
| 2022 | 21.83M | +7.41% |
| 2021 | 20.32M | +0.00% |
| 2020 | 20.32M | +0.00% |
| 2019 | 20.32M | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
23andMe Holding Co. Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Shares Outstanding FAQ
- What is the shares outstanding for 23andMe Holding Co. (ME)?
- The shares outstanding for ME stock is 0.03.
- Is 23andMe Holding Co.'s shares outstanding high or low?
- 23andMe Holding Co.'s shares outstanding of 0.03 is 15% above its 5-year average of 0.02, near the high end of its 5-year range (0.02–0.03).
- What is the TTM average shares outstanding for 23andMe Holding Co. (ME)?
- The TTM average shares outstanding for ME stock is 0.02.
- What is the 3Y average shares outstanding for 23andMe Holding Co. (ME)?
- The 3Y average shares outstanding for ME stock is 0.02.
- What is the 5Y average shares outstanding for 23andMe Holding Co. (ME)?
- The 5Y average shares outstanding for ME stock is 0.02.
23andMe Holding Co. Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-03-31 | 0.03 |
| 2024-03-31 | 0.02 |
| 2023-03-31 | 0.02 |
| 2022-03-31 | 0.02 |
| 2021-03-31 | 0.02 |
| 2020-03-31 | 0.02 |
| 2019-03-31 | 0.02 |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage